AlloSure And AlloMap Will Boost Molecular Transplant Care Despite Hurdles
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
10 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$28.00
53.7% undervalued intrinsic discount21 Aug
US$12.97
1Y
-58.9%7D
9.5%